The insurers I’ve seen that have already listed Daybue on their formulary lists not only require Prior Authorisation - meaning the treating physician must obtain advance approval from the health insurer to determine if the patient qualifies for payment coverage - but also limit quantity to a 30 day supply per fill. One fund states that the quantity limit is to monitor possible adverse effects and to avoid medication waste.
The insurers I’ve seen that have already listed Daybue on their...
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.48 |
Change
0.375(1.87%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.245M | 61.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 196 | $20.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.49 | 192 | 7 |
View Market Depth
| Last trade - 12.56pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |